CK1α与IRF4是原发性渗出性淋巴瘤中免疫调节药物的关键且独立效应分子
原发性渗出性淋巴瘤(PEL)治疗选择有限。基于全基因组CRISPR/Cas9筛选及验证实验,在4种新底物中仅CK1α对PEL细胞系存活必需,IKZF1和IKZF3单独或联合均非必需;IRF4在所有8株PEL细胞系中均关键,且IMiDs独立于IKZF1/IKZF3下调IRF4。CK1α和/或IRF4再表达可部分挽救IMiD毒性。结论:IMiD对PEL细胞系的毒性不依赖IKZF1/IKZF3,而是通过降解CK1α和下调IRF4。
要点
- 在PEL细胞系中,4种新底物里仅CK1α对存活必需。
- IKZF1和IKZF3单独或联合对PEL细胞系存活均非必需。
- IRF4在全部8株PEL细胞系中均关键,IMiDs独立于IKZF1/IKZF3下调IRF4。
核心结论
- IMiD对PEL细胞系的毒性不依赖IKZF1和IKZF3,而是通过降解新底物CK1α和下调IRF4实现。
研究设计与样本
- 基于全基因组CRISPR/Cas9筛选必需人类基因,并在PEL细胞系中进行广泛验证实验。
主要发现
- 在4种新底物中,仅CK1α对PEL细胞系存活必需,IKZF1和IKZF3单独或联合均非必需。
- IRF4在全部8株受试PEL细胞系中均关键。
- IMiDs独立于IKZF1和IKZF3触发IRF4表达下调。
- CK1α和/或IRF4再表达可部分挽救PEL细胞系免受IMiD介导的毒性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary effusion lymphoma (PEL) is an aggressive cancer with few treatment options. The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide have recently been shown to kill PEL cell lines, and lenalidomide is in clinical trials against PEL. IMiDs bind to the CRL4CRBN E3 ubiquitin ligase complex, leading to the acquisition of the Ikaros family zinc finger proteins 1 and 3 (IKZF1 and IKZF3), casein kinase 1 α (CK1α), and zinc finger protein 91 (ZFP91) as neosubstrates. IMiDs are effective against multiple myeloma because of degradation of IKZF1 and IKZF3 and the consequent loss of interferon regulatory factor 4 (IRF4) and MYC expression. Lenalidomide is also effective in chromosome 5q deletion-associated myelodysplastic syndrome as a result of degradation of CK1α. An essential IKZF1-IRF4-MYC axis has recently been proposed to underlie the toxicity of IMiDs in PEL. Here, we further investigate IMiD effectors in PEL cell lines, based on genome-wide CRISPR/Cas9 screens for essential human genes. These screens and extensive validation experiments show that, of the 4 neosubstrates, only CK1α is essential for the survival of PEL cell lines. In contrast, IKZF1 and IKZF3 are dispensable, individually or in combination. IRF4 was critical in all 8 PEL cell lines tested, and surprisingly, IMiDs triggered downregulation of IRF4 expression independently of both IKZF1 and IKZF3. Reexpression of CK1α and/or IRF4 partially rescued PEL cell lines from IMiD-mediated toxicity. In conclusion, IMiD toxicity in PEL cell lines is independent of IKZF1 and IKZF3 but proceeds through degradation of the neosubstrate CK1α and downregulation of IRF4.
引用
- Patil A, Manzano M, Gottwein E, et al. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma. Blood. 2018. PMID: 29954751. doi:10.1182/blood-2018-01-828418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。